Biosimilars in Retina Care: What Your Practice Needs to Know
A Retina Alliance member briefing
Biosimilars are no longer a someday conversation. We now have three interchangeable ranibizumab products on the market, six FDA-approved aflibercept (Eylea 2mg) biosimilars in the wings, a wave of launches scheduled across late 2026 and into 2027, and a Medicare payment window that meaningfully changes the math — but only for a limited time. For independent retina practices, the difference between treating this proactively and reacting to it is real money and real exposure. Here's what matters.
What a biosimilar actually is (and isn't)
A biosimilar is not a generic. It's a biologic shown through extensive analytical, structural, and pharmacokinetic characterization to have no clinically meaningful differences from its reference product in safety, purity, and potency. The molecules are highly similar, not chemically identical, because biologics can't be copied atom-for-atom the way a small-molecule generic can. The practical takeaway for us: the comparability bar is rigorous, and real-world switching data out of Europe and the U.S. over the past decade has been reassuring on immunogenicity and efficacy. The clinical question is largely settled. The economic and access questions are where the action is.
The landscape today
Ranibizumab (Lucentis). Three biosimilars are FDA-approved and designated interchangeable: Cimerli (first to interchangeability, 2022), Byooviz, and Nufymco (approved December 2025). These have been commercially available and clinically de-risked. Notably, despite years on the market, biosimilar uptake against Lucentis has hovered around a quarter of the market — a telling signal about the economics we'll get to below.
Aflibercept (Eylea 2mg). This is the more consequential front. Six biosimilars are FDA-approved — Yesafili, Opuviz, Ahzantive, Enzeevu, Pavblu, and Eydenzelt — but approved does not mean available. As of now, Amgen's Pavblu is the only aflibercept biosimilar to have actually launched in the U.S., which it did after the Federal Circuit declined to enjoin it. The rest are gated by patent litigation and settlement-driven launch dates: Yesafili in the second half of 2026, Ahzantive and Enzeevu in Q4 2026, Opuviz pushed to January 2027, and Eydenzelt still uncertain pending litigation.
Bevacizumab (Avastin). Worth a footnote: compounded off-label bevacizumab remains the low-cost anti-VEGF workhorse. Avastin biosimilars exist for oncology but aren't used intravitreally, and on-label ophthalmic bevacizumab is a separate regulatory story. For biosimilar strategy, ranibizumab and aflibercept-2mg are the two molecules that matter.
Why "approved" hasn't meant "available": the Regeneron factor
The single biggest reason most aflibercept biosimilars aren't on your shelf is litigation. Regeneron has asserted a dense patent thicket — reportedly as many as 46 patents, some extending to 2040 — and has pursued BPCIA litigation aggressively. The result is a market where launch timing is being set by settlement agreements, not by FDA approval dates. A few manufacturers have launched (or could launch) "at risk," but most have negotiated defined entry windows. Practical implication: don't let approval headlines drive stocking decisions. Track which products can actually be purchased and when, because the gap between approval and availability is often a year or more.
Interchangeability — and why it matters far less for us than the headlines suggest
Interchangeability is a specific FDA designation that permits pharmacy-level substitution without prescriber intervention, subject to state law. It was historically a higher bar requiring dedicated switching studies.
Two things you should know:
First, the FDA is dismantling the distinction. Draft guidance in June 2024 removed the switching-study expectation, and in October 2025 the FDA went further — proposing to eliminate comparative efficacy studies for most biosimilars and to merge the biosimilar and interchangeable standards entirely, even removing interchangeability language from labeling. The agency's position, in plain terms, is that a protein is a protein: if the analytics prove sameness, the clinical switching data adds little. Implementation is expected through 2026.
Second — and this is the part that gets lost — interchangeability is largely irrelevant to buy-and-bill retina. That designation governs what a pharmacist can substitute. We administer these drugs in office and select the product ourselves. The physician chooses, acquires, and bills. So the question for us is never "can the pharmacy swap it," it's "does the product I choose to stock make clinical and financial sense." Don't let the interchangeability conversation distract from the real decision.
The economics — this is what actually drives the decision
Here's the structural reality every independent practice needs to internalize:
Each biosimilar gets its own ASP and its own J-code. Unlike generics, biosimilars sharing a reference product are not blended into one billing code. Pricing and reimbursement are tracked product by product.
The IRA add-on is the current sweetener — and it's temporary. Qualifying biosimilars (those priced at or below the reference product's ASP) are reimbursed at ASP + 8% of the reference product's ASP, rather than the usual ASP + 6%, for a five-year window. Products already paid under ASP as of late 2022 carry this through September 30, 2027; products launching before December 31, 2027 get five years from their first ASP quarter. Anything launching after that reverts to ASP + 6%. There is a closing door here, and the aflibercept biosimilars launching in 2026–2027 are stepping through it.
The buy-and-bill "perverse incentive" is the reason uptake has lagged. Because the add-on is a percentage of price, a higher-priced reference drug generates more absolute add-on dollars than a cheaper biosimilar. That's precisely why ophthalmology has been slow to adopt — the economics have historically rewarded staying on the reference product. The IRA's reference-based 8% was designed to blunt this, but it doesn't eliminate it.
ASP erodes. As biosimilars compete, ASPs fall, which drags down both acquisition cost and reimbursement over time. The margin picture at launch is not the margin picture eighteen months later. Model the trajectory, not just the snapshot.
What's not affected — and why it matters strategically
There are no biosimilars for Eylea HD (aflibercept 8mg) or Vabysmo (faricimab). These are newer molecules and doses still under patent protection. As 2mg aflibercept faces biosimilar erosion, expect continued commercial pressure to migrate patients toward the higher-dose and longer-durability branded options — a dynamic that's as much about manufacturer lifecycle strategy as it is about clinical durability. Keep that lens on as detailing intensifies.
What this means for your practice
Model margin by product and payer mix before you switch anything. The right answer depends on your Medicare-versus-commercial split and your specific contracts. There is no universal "biosimilars save money for everyone" — for a buy-and-bill practice, that's an empirical question about your numbers.
Separate "approved" from "available." Build your stocking decisions around what you can actually purchase and the launch windows that are locked in, not press releases.
Watch the 2027 cliff. The enhanced ASP + 8% add-on is a time-limited advantage. It should factor into when and how you adopt.
Anticipate payer mandates. Commercial step-therapy and formulary pressure favoring biosimilars is coming as more products launch. Better to have your economics modeled before a payer forces the question.
Use collective leverage. Acquisition pricing, rebate structures, and contracting terms are where biosimilar economics are won or lost — and where scale matters most. This is exactly the kind of decision our members are positioned to navigate together rather than one practice at a time.
Bottom line
The clinical case for biosimilars is essentially made. The strategic case is entirely about access timing, reimbursement windows, and acquisition economics — and all three are moving fast. The practices that come out ahead will be the ones that model their own numbers, distinguish approval from availability, and act inside the IRA window rather than after it closes. Retina Alliance exists to make sure our members are making those calls with the best pricing, the best information, and the leverage of the group behind them.
